Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

B. Riley Downgrades Dicerna Pharmaceuticals to Neutral from Buy After Announcing $3.3 Billion Sale to Novo Nordisk, Lifts PT to $38.25 from $35

11/19/2021 | 09:22am EST


ę MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2020 164 M - -
Net income 2020 -113 M - -
Net cash 2020 517 M - -
P/E ratio 2020 -14,5x
Yield 2020 -
Capitalization 2 986 M 2 986 M -
EV / Sales 2019 49,5x
EV / Sales 2020 6,92x
Nbr of Employees 302
Free-Float 92,6%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Bob D. Brown President
Douglas W. Pagßn Chief Financial Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
James B. Weissman Chief Operating Officer & Executive Vice President
Jamie Haney Director
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.0.00%2 986
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-9.18%51 206
BIONTECH SE-39.28%37 805